Indonesia Pharmaceutical Market will be led by Growing Generic Drugs and Bio-pharmaceutical Market: Ken Research

1
Indonesia Pharmaceutical Market will be led by
Growing Generic Drugs and Bio-pharmaceutical
Market Ken Research
2
Expansion of product portfolio by major
pharmaceutical companies and increase in demand
for generic drugs were the key factors driving
growth in Indonesia pharmaceutical Market. The
report titled Indonesia Pharmaceutical Market
Outlook to 2022 - By Therapeutic Segment
(Anti-Infectives, Gastrointestinal and
Metabolism, Cardiovascular System, Central
Nervous System, Respiratory, Musculoskeletal,
Dermatology, Genitourinary and Hormones, Blood,
Oncology), By Domestic and International Players,
By Generic and Patent Drugs, By OTC
Prescription Drugs, By Region by Ken Research
suggested a growth at a CAGR of 10.0 in revenue
in Indonesia Pharmaceutical Market by 2022.
3

• Indonesia healthcare market has observed a
  favorable growth in the last 5 years. The market
  is still under penetrated especially in the tier
  2 areas in Indonesia as of 2017.
• The launch and execution of JKN scheme by the
  government has led to surge in demand for primary
  healthcare facilities and increased generic drug
  sale. The market has underscored various
  deregulation programs which has stimulated
  foreign investment in the industry.
• Indonesia Pharmaceutical market is dominated by
  domestic players which controlled majority of the
  market in 2017. Recent favorable government
  regulations have facilitated the entry of foreign
  players in the space. There are 206
  pharmaceutical companies (182 domestic and 24
  international companies) located in Indonesia.
• The market is driven by deregulation in FDI
  regulations in pharmaceutical and favorable
  government policies leading to increase

4

• sale of generic drugs. Increased investment in
  innovation of new drugs with higher margin led to
  increased profitability of pharmaceutical
  companies. Expansion of major companies through
  mergers, acquisitions and alliances has enabled
  companies to manufacture high end medicines and
  pharmaceutical products.
• The local companies largely focus on generic
  drugs manufacturing that are dependent on
  imported active pharmaceutical ingredients (API),
  mainly from China and India.
• As Jaminan Kesehatan Nasional (JKN) has
  prioritized the use of generic drugs, the demand
  for unbranded generic drugs has grown as
  Indonesians increasingly rely on generic drugs.
  This has augmented the domestic players sales.
  But at the same time, the market has also
  witnessed an increase in number of new players
  which has driven down the margins. Since the
  product portfolio of majority domestic
  pharmaceutical companies is dominated by generic
  drugs, the sales

5

• have gone up since 2014. Moreover, the prices of
  generic drugs are regulated and consistent across
  Indonesia whereas the prices increase by 10 for
  branded drugs annually. Domestic players have
  witnessed success in rural areas of Indonesia.
  Due to inaccessibility and language barrier
  existing in the rural areas, the domestic players
  have been better able to bridge the gap as
  compared to international players. The domestic
  players have also dominated the Over the Counter
  drugs which are driven by the increasing self
  medication behavior of the population. Domestic
  players dominate the Anti-Infectives,
  Gastrointestinal and metabolism and respiratory
  therapeutic segments.
• Indonesia biopharmaceutical industry is in the
  nascent stage. There is a strong interest from
  research-based global biopharma companies to
  conduct clinical research in Indonesia because of
  the large concentrated patient populations and
  disease profiles. Furthermore, as the industry
  intends to move towards self sufficiency,
  Indonesian

6
government released the 11th economic stimulus
package with the aim of boosting the domestic
production of medicines' raw materials,
particularly for five product categories namely
biotechnology, vaccines, herbal extracts, active
pharmaceutical ingredients and medical
devices. In order to tap the existing potential,
large domestic pharmaceutical companies have tied
up with international players to manufacture
biopharmaceutical products for the treatment of
chronic diseases such as cancer, kidney failure
and others. ProBioGen AG, a CDMO based in
Germany, and Bio Farma, a state-owned vaccine
manufacturer in Indonesia, has signed an
agreement to develop a biosimilar to the
monoclonal antibody (mAb) trastuzumab for cancer
treatment that will be produced in Indonesia.
7
Kalbe Farma has also launched biosimilar version
of insulin in Indonesia to treat diabetes
mellitus which is 38 cheaper than the existing
insulin. Biosimilars are cheaper imitations of
drugs known as biologics. Kalbe Farma set up its
biological drug factory, PT Kalbio Global Medika
in Cikarang, Bekasi, with an investment value
that ranges between USD 30 to USD 35 million. The
factory is built under the joint venture between
Kalbe and a South Korean pharmaceutical company
Genexine Inc, PT Kalbe-Genexine Biologics Key
Topics Covered in the Report Indonesia Dietary
Vitamin Supplements Market Pharmaceutical Market
Size Indonesia Indonesia Vaccine Market Indonesia
Pharmaceutical Regulations Number of
Pharmaceutical Companies Indonesia
8
Indonesia Pharmaceutical Market Players Obese
Population Indonesia Generic Drug Market Size
Indonesia Number of Healthcare Centers in
Indonesia Budget Allocation on Healthcare
Indonesia Healthcare Spending Indonesia Vitamin
and Dietary Supplement Market Indonesia For more
information on the research report, refer to
below link https//www.kenresearch.com/healthcare
/pharmaceuticals/indonesia-pharmaceutical-market/1
43542-91.html Related Reports by Ken
Research https//www.kenresearch.com/healthcare/ge
neral-healthcare/saudi-arabia-healthcare-market-re
search-report/1106-91.html
9
https//www.kenresearch.com/healthcare/general-hea
lthcare/uae-healthcare-market-report/37505-91.html
https//www.kenresearch.com/healthcare/general-h
ealthcare/qatar-healthcare-market-report/99730-91.
html Contact Ken Research Ankur Gupta, Head
Marketing Communications sales_at_kenresearch.com
91-124-4230204
10
(No Transcript)